Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04482010
Other study ID # ANRS 12392
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 29, 2020
Est. completion date December 28, 2022

Study information

Verified date February 2021
Source ANRS, Emerging Infectious Diseases
Contact Luis Sagaon Teyssier, PhD
Phone +223 94 00 45 63
Email luis.sagaon-teyssier@inserm.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sanu Gundo ANRS 12392 is a non-randomized and non-comparative intervention trial in Mali. The main objective of the project is to study the feasibility of the community-based HIV care in the context of the artisanal gold mining zones and to evaluate its contribution to the linkage-to-care of PLWHIV with the health system and their retention in care, as well as its effect on their health status.


Description:

Convergence of key-populations in the informal gold mining zones suggests the important exposure to HIV contamination of people living in these zones. The pilot project Sanu Gundo showed a prevalence of 8% in the site of Kokoyo, much higher than the 1.1% national prevalence. The large rates of HIV patients lost to followup underline the difficulties experienced by the health system. Introducing a community-based HIV care offer in proximity to people in the informal gold mining zones could contribute to the improvement not only of access to HIV prevention and testing, but also to the access and retention in care. Sanu Gundo ANRS 12392 is a non-randomized and non-comparative intervention trial. Community-based activities conducted by ARCAD Santé PLUS (during 5 months) including HIV testing will contribute to the construction of both a control and intervention groups. These groups will be formed by people tested positive to HIV during the community-based activities conducted by ARCAD Santé PLUS in two artisanal gold mining sites. The control group will include 129 participants positive to HIV in Diassa (Sikasso region), and the intervention group will include 136 participants positive to HIV in Kofoulatiè (Koulikoro region). The intervention consists local community-based activities for HIV care provided by ARCAD Santé PLUS for people living in Kofoulatiè (intervention group), whereas people living in Diassa (control group) will be referred to the Referral Health Centers (CSRéf) as recommended by the national guidelines. The total number of 265 participants diagnosed positive to HIV enrolled in the study corresponds (at least) to the HIV prevalence of 3% observed during the first two months of participants enrolment (November 2020 to January 2021). Accounting for survey attrition, refusal of the community-based HIV care and non-inclusion criteria, it is expected that 172 participants (86 per group) will be followed-up during the whole duration of the study. This corresponds to the number of participants required to verify the primary endpoint of the study: a better retention rate in healthcare 12 months after of HIV diagnosis for people receiving community-based care by ARCAD Santé PLUS. A quantitative survey will be conducted with the administration of questionnaires at different point-times during the follow-up for HIV care: M1 (first contact with the healthcare system and linkage-to-care), M3 (linkage-to-care and initiation of ARV treatment), M6, M9 and M12 (medical follow-up and retention in care). Blood samples will be collected using Dried Blood Spot testing (DBS) at enrolment, M6 and M12. Furthermore, data will be collected about the characteristics of the healthcare centers around the artisanal gold mining sites (i.e. healthcare supply) and the costs of community-based HIV care. The results will overcome the lack of epidemiological data about HIV in the informal gold mining zones, about the way in which PLWH are linked-to-care, and about the extent of the PLWH loss to follow-up. The results will also allow both testing the feasibility of the implementation of proximity community-based services for HIV care in the informal gold mining zones, and evaluating their contribution to retention of PLWH in care. The success of this project could allow extending the proposed strategy to other informal gold mining zones in Mali.


Recruitment information / eligibility

Status Recruiting
Enrollment 265
Est. completion date December 28, 2022
Est. primary completion date March 28, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - To live and/or to work in the sites of Kofoulatiè or Diassa (Mali) - To be diagnosed positive to HIV by ARCAD Santé PLUS (screening and enrolment tests positive) - To be 18 years or older - To speak one of the most common languages (Bambara, French or English) and to be able of providing informed consent In addition, to be included in the intervention group, people living with HIV in the Kofoulatiè site must accept the community-based HIV care provided by ARCAD Santé PLUS Exclusion Criteria: - Women pregnant at the time of the HIV screening test by ARCAD Santé PLUS, or needing ultrasound to confirm pregnancy - People with discordant screening and enrolment tests - People inebriated or under the influence of drugs at enrolment - Adults not able to understand and/or to provide informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Local community-based HIV care
Compared to the classic HIV care, community-based HIV care includes: Individual interviews with a psychosocial agent; Support groups conducted by psychosocial agents; Culinary workshops gathering PLWHIV and healthcare professionals; Home visits by a community worker; Emergency relief based on a funding for patients with urgent needs As in the classic HIV care, ARCAD Santé PLUS provides consultations with doctors, prescriptions and delivery of antiretroviral (ARV) treatment every 3 months, biological analyses for enrolment, and follow-up every 6 months. In addition, psychosocial agents from ARCAD Santé PLUS propose workshops on education and support for adherence to treatment.

Locations

Country Name City State
Mali ARCAD Santé PLUS mobile care unit for recruitment of participants (Diassa, control site) Diassa Sikasso
Mali ARCAD Santé PLUS mobile care unit for community-based HIV care and study follow-up (Kofoulatiè, intervention site) Kofoulaté Koulikoro
Mali ARCAD Santé PLUS mobile care unit for recruitment of participants (Kofoulatiè, Intervention site) Kofoulaté Koulikoro
Mali Referral health center (CSRéf) Kolondieba, classic HIV care Kolondieba Sikasso

Sponsors (4)

Lead Sponsor Collaborator
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) ARCAD Santé PLUS, SEREFO, UMR 1252 SESSTIM

Country where clinical trial is conducted

Mali, 

Outcome

Type Measure Description Time frame Safety issue
Other Material and human resources available for healthcare supply around gold-mining zones Description of the healthcare supply geographical distribution around the artisanal gold-mining zones included in the study;
Description of the available human and material resources in the healthcare centers around the artisanal gold-mining zones included in the study
From enrolment (M0) to 12 months after HIV diagnosis (M12)
Other Working conditions of healthcare professionals involved in the classic HIV care Description of the socioeconomic and demographic characteristics of healthcare professionals in HIV care centers around the artisanal gold-mining zones included in the study;
Number of working hours, number of medical visits, earnings, perceived health status, etc.
From enrolment (M0) to 12 months after HIV diagnosis (M12)
Primary Lost to follow-up rate 12 months after the HIV diagnosis It was defined on the basis of existing data: 1) lost to follow-up rate in HIV care at the national level in Mali (32% in 2019); 2) lost to follow-up rate in the HIV care of ARCAD Santé PLUS in urban areas (12% in 2019).
The primary endpoint is : the lost to follow-up rate in the community-based HIV care 12 months after diagnosis is (at least) 20 percentage points lower than the lost to follow-up rate in the classic HIV care.
12 months after HIV diagnosis (M12)
Secondary Extent of the HIV epidemic in the artisanal gold-mining sites This outcome provides the prevalence of the HIV epidemic among people living/working in the artisanal gold-mining sites:
number of HIV positive tests as percentage of the total number of people living/working in the sites
At enrolment (M0)
Secondary Comparing linkage-to-care and retention between classic and community-based HIV care For linkage-to-care:
Percentage of people living with HIV starting a treatment 1 month and 3 months after diagnosis
Percentage of people living with HIV with available blood tests (CD4 count, Viral load, etc) at the beginning of ARV treatment
For retention in care:
% of people living with HIV present for HIV care visits at 3, 6, 9 and 12 months after diagnosis
1 month after HIV diagnosis (M1) and 12 months after HIV diagnosis (M12)
Secondary Comparing the impact of classic and community-based HIV care on virological succes, behavioral and psychosocial outcomes CD4 count and viral load at the time of diagnosis (M0) and its evolution 6 and 12 months later (M6 and M12)
Self-perception of health status, sexual behavior indicators at M1 and evolution at M12: number of partners, number of sexual intercourses, etc.
From enrolment (M0) to 12 months after HIV diagnosis (M12)
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2